Gilead Sciences is teaming up with Vir Biotechnology to develop new cancer treatments.
Gilead Sciences Inc has announced a collaboration with Vir Biotechnology to create dual-masked T-cell engagers aimed at treating solid tumors. This partnership is part of a licensing deal potentially worth up to $1.9 billion, showing Gilead's commitment to expanding its oncology portfolio. The stock closed at $152.41, reflecting a 1.67% decrease on the day of the announcement.
Investor takeaway: Keep an eye on this partnership, as it may impact Gilead's future market position.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$186.53B
Div. yield
2.13%
Div. / share
$3.22
52W high
$154.51
52W low
$111.27
1W change
+2.56%
Beta
0.33
Analyst Price Targets
Based on 28 analysts covering GILD · as of Oct 14, 2026
Wall Street analysts forecast GILD stock price to rise 435.4% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$159.62
+435.4% Upside
Previously C$159.38 on Oct 12, 2026
Current Price
C$29.81
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
21.4%
Annualized
90-Day Vol
27.5%
Annualized
Trend (90d)
+46.4%
Annualized drift
90d Mean
C$174.55
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$156.31 | C$145.17 – C$168.31 |
| 60 trading days | C$165.18 | C$148.78 – C$183.39 |
| 90 trading days | C$174.55 | C$153.56 – C$198.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Gilead's Stock Down 1.67% Despite New Collaboration
Gilead's stock closed at $152.41, down 1.67% for the day, with a trading volume of 1,753,202 shares, which is below the 20-day average of 5,872,763 shares.
Partnership Details
On October 14, 2026, Gilead Sciences and Vir Biotechnology announced a strategic partnership focused on developing dual-masked T-cell engagers for solid tumors. The collaboration includes a licensing agreement valued at up to $1.9 billion. This partnership aims to combine both companies' expertise in immunotherapy to create innovative cancer treatment solutions. Gilead's stock has increased by 23.83% year-to-date, indicating strong market interest in its growth strategies.
Advertisement
Market Reaction
After the announcement, Gilead's stock closed at $152.41, marking a 1.67% decrease for the day. The trading volume reached 1,753,202 shares, which is 0.95 times the 20-day average volume of 5,872,763 shares, suggesting lower trading activity in response to the news. Currently, Gilead's stock is trading above its 50-day moving average of $145.12 and its 200-day moving average of $137.44, indicating a solid position relative to its recent performance.
Looking Ahead
As Gilead and Vir Biotechnology advance their collaboration, investors will likely watch for future announcements regarding clinical trials and developments related to the T-cell engager therapies. The average analyst target for Gilead's stock is $159.62, suggesting a potential upside of 4.7% from the current price. The success of this partnership could significantly influence Gilead's market position in the oncology sector and its overall revenue growth as it seeks to expand its therapeutic offerings.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
